| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Hopfner Robert Lorne | Director | C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON | /s/ Sanjay Subramanian, as attorney-in-fact for Robert Hopfner | 2025-07-03 | 0001551966 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INZY | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -$11.7M | -2.92M | -100% | $4.00 | 0 | Jul 1, 2025 | By Pivotal | F1, F2, F3, F4, F5 |
| transaction | INZY | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -$6.29M | -1.57M | -100% | $4.00 | 0 | Jul 1, 2025 | By Pivotal | F1, F2, F4, F5, F6 |
Robert Hopfner is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). |
| F2 | Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| F3 | Held directly by Pivotal bioVenture Partners Fund I, L.P. |
| F4 | The general partner of Pivotal bioVenture Partners Fund I, L.P and Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). |
| F5 | Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein. |
| F6 | Held directly by Pivotal bioVenture Partners Fund II, L.P. |